V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 320003046 | 320001821 | 1.54 | 74.6 | Palliative (P) | null | 2018-06-18 | Sorafenib | N | N | 320017902 | TEMOZOLOMIDE + RT |
| 320003047 | 320001822 | 1.68 | 106 | Disease modification (D) | 2017-10-13 | 2017-10-14 | Cisplatin + Docetaxel +Fluorouracil | N | N | 320017909 | MITOMYCIN |
| 320003048 | 320001823 | 1.5 | 79.9 | Not known (9) | 2015-07-17 | 2015-07-21 | FLUOROURACIL + IRINOTECAN | 2 | Y | 320017913 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 320003049 | 320001824 | 1.79 | 93.8 | Not known (9) | 2016-03-30 | 2016-04-08 | ECX | 02 | N | 320017920 | TRASTUZUMAB |
| 320003050 | 320001825 | 1.6 | 54.45 | Palliative (P) | null | 2017-12-07 | Carboplatin+Fluorouracil 4 or 5 day | null | null | 320017939 | CARBO + FLUOROURACIL |
| 320003051 | 320001826 | 1.8 | 81 | Curative (C) | 2018-11-17 | 2018-11-19 | Bevacizumab + CAPECITABINE + IRINOTECAN | 2 | N | 320017944 | CISPLATIN + GEMCITABINE |
| 320003053 | 320001828 | 1.57 | 104.7 | Palliative (P) | 2014-09-11 | 2014-09-13 | Cisplatin + Gemcitabine (D 1 & 8) | 02 | null | 320017949 | IVADO |
| 320003054 | 320001829 | 1.84 | 66.1 | Palliative (P) | 2017-09-12 | 2017-09-22 | Capecitabine + Oxaliplatin 21day | N | N | 320017955 | CISPLATIN + GEMCITABINE |
| 320003055 | 320001830 | 1.7 | 44.85 | null | 2015-12-04 | 2015-12-25 | Cisplatin + Gemcitabine (D 1 & 8) | N | N | 320017956 | PEMBROLIZUMAB |
| 320003056 | 320001831 | 1.75 | null | Curative (C) | 2016-02-24 | 2016-03-20 | CARBOPLATIN + Cetuximab + FLUOROURACIL | N | N | 320017963 | BCG |
| 320003057 | 320001832 | 1.67 | 86 | Palliative (P) | 2013-09-06 | 2013-09-16 | Carboplatin+Fluorouracil 4 or 5 day | N | N | 320017967 | DOXORUBICIN EMBOLISATION |
| 320003058 | 320001832 | 1.56 | 75.4 | Palliative (P) | 2016-11-27 | 2016-12-19 | Trial Unspecified | N | N | 320017967 | CARBOPLATIN + CETUXIMAB + FLUOROURACIL |
| 320003059 | 320006309 | 1.25 | -1 | Palliative (P) | 2018-09-01 | 2018-09-22 | Doxorubicin + Ifosfamide | N | N | 320017971 | TRASTUZUMAB |
| 320003060 | 320001833 | null | null | Neo-adjuvant (N) | 2016-07-30 | 2016-07-30 | Capecitabine | null | null | 320017986 | ICON TRIAL |
| 320003061 | 320001834 | null | 111.8 | Neo-adjuvant (N) | null | 2015-02-17 | Abiraterone | null | null | 320017994 | PEMBROLIZUMAB |
| 320003062 | 320001835 | 1.65 | 65.5 | Disease modification (D) | null | 2018-05-18 | IMATINIB | N | N | 320017997 | CETUXIMAB + RT |
| 320003063 | 320001835 | null | 67.3 | Palliative (P) | null | 2017-02-22 | CISPLATIN + GEMCITABINE | null | null | 320017997 | VISMODEGIB |
| 320003064 | 320006310 | 1.62 | 66.7 | Palliative (P) | 2015-08-30 | 2015-08-31 | Bevacizumab+Carbo+Pacliaxel | N | N | 320018017 | CARBOPLATIN + ETOPOSIDE |
| 320003065 | 320001836 | 1.72 | 76.9 | Neo-adjuvant (N) | null | 2016-04-21 | Trial Unspecified | N | N | 320018027 | CAPECITABINE + CARBOPLATIN |
| 320003066 | 320001837 | null | 53 | Curative (C) | 2013-01-27 | 2013-02-09 | Sorafenib | null | null | 320018039 | CARBOPLATIN + RT |
| 320003067 | 320001837 | 1.63 | 65.1 | Curative (C) | 2016-03-08 | 2016-03-09 | Capecitabine + Cisplatin | N | N | 320018039 | CETUXIMAB |
| 320003068 | 320001837 | 1.63 | null | null | 2013-03-05 | 2013-04-01 | Paclitaxel 80mg/m2 day 1 8 15 | N | Y | 320018039 | CETUXIMAB + RT |
| 320003069 | 320001838 | 1.7 | 80.8 | Palliative (P) | 2018-07-03 | 2018-07-03 | PEMBROLIZUMAB | 02 | N | 320018054 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 320003070 | 320001839 | 1.83 | 60 | Neo-adjuvant (N) | 2017-12-12 | 2017-12-18 | CARBOPLATIN + RT | N | N | 320018066 | IDELALISIB + RITUXIMAB |
| 320003071 | 320001839 | 1.73 | 53 | Palliative (P) | 2018-05-11 | 2018-05-15 | Cetuximab 7 day (Cycle 1) | 02 | N | 320018066 | CARBOPLATIN + ETOPOSIDE |
| 320003072 | 320001839 | 1.64 | 70.3 | Palliative (P) | 2013-10-24 | 2013-10-25 | Bevacizumab | 02 | N | 320018066 | RITUXIMAB |
| 320003073 | 320001840 | 1.62 | 79.7 | Palliative (P) | 2016-09-19 | 2016-10-03 | CARBOPLATIN + Cetuximab + FLUOROURACIL | N | N | 320018083 | LANREOTIDE |
| 320003074 | 320001841 | null | 79.6 | null | 2013-04-25 | 2013-12-05 | Carbo F | N | N | 320018094 | CARBOPLATIN + ETOPOSIDE |
| 320003075 | 320001842 | 1.53 | 0 | Disease modification (D) | 2017-12-19 | 2017-12-26 | Bevacizumab+Carbo+Pacliaxel | N | N | 320018095 | VIDE |
| 320003076 | 320004938 | null | 85.6 | Palliative (P) | 2016-07-07 | 2016-08-03 | Carboplatin+Fluorouracil 4 or 5 day | Y | N | 320018100 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 320003077 | 320001843 | 1.71 | 49 | Palliative (P) | 2017-09-09 | 2017-09-23 | Cisplatin + Pemetrexed | 02 | N | 320018104 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 320003078 | 320004939 | 1.66 | 62 | Palliative (P) | 2016-07-01 | 2016-07-21 | Trial Unspecified | N | N | 320018109 | TEMOZOLOMIDE + RT |
| 320003079 | 320004939 | 1.72 | 0 | Neo-adjuvant (N) | 2015-09-04 | 2015-09-07 | Cisplatin + Docetaxel +Fluorouracil | N | N | 320018109 | TRIAL |
| 320003080 | 320004939 | 0 | 61.5 | Palliative (P) | 2014-07-11 | 2014-07-28 | Capecitabine+Cisplatin+Streptozocin | N | N | 320018109 | CVD |
| 320003081 | 320001844 | 1.67 | 101 | Palliative (P) | 2018-09-01 | 2018-09-20 | CISPLATIN + DOCETAXEL + FLUOROURACIL | 02 | Y | 320018136 | FLUOROURACIL + MITOMYCIN + RT |
| 320003082 | 320001845 | 1.66 | 87.2 | Neo-adjuvant (N) | 2017-02-03 | 2017-02-10 | Enzalutamide | Y | N | 320018139 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 320003083 | 320001846 | 1.67 | 104.5 | Curative (C) | 2014-04-04 | 2014-04-28 | CISPLATIN + GEMCITABINE | 2 | N | 320018148 | CISPLATIN + ETOPOSIDE |
| 320003084 | 320004940 | null | 108.35 | null | 2013-08-19 | 2013-08-28 | CETUXIMAB | N | N | 320018151 | CAPECITABINE + CETUXIMAB + CISPLATIN |
| 320003085 | 320001847 | 1.7 | 53.4 | Curative (C) | 2017-05-07 | 2017-05-25 | BCG Intravesical | N | Y | 320018153 | CISPLATIN + PEMETREXED |
| 320003086 | 320001847 | 1.65 | 77.9 | Palliative (P) | 2015-10-30 | 2015-11-20 | POUT TRIAL | N | N | 320018153 | CISPLATIN + VINORELBINE |
| 320003087 | 320006314 | 1.61 | 58.5 | Palliative (P) | 2017-09-23 | 2017-09-24 | DOXORUBICIN | 2 | N | 320018203 | CARBOPLATIN + CETUXIMAB + FLUOROURACIL |
| 320003088 | 320006940 | null | null | Not known (9) | 2015-07-26 | 2015-08-07 | CETUXIMAB | N | null | 320018227 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 320003089 | 320001848 | 1.84 | 24.5 | Palliative (P) | 2018-06-20 | 2018-07-09 | CISPLATIN + DOCETAXEL + FLUOROURACIL | Y | N | 320018232 | CISPLATIN + GEMCITABINE |
| 320003090 | 320004942 | 1.74 | 93.8 | Curative (C) | 2014-04-14 | 2014-04-15 | PEMBROLIZUMAB | 02 | N | 320018235 | CISPLATIN + GEMCITABINE |
| 320003091 | 320001849 | 0 | 79.4 | Adjuvant (A) | 2016-01-20 | 2016-01-22 | Carboplatin + Etoposide IV 3 day | 2 | Y | 320018237 | OXALIPLATIN + MDG |
| 320003094 | 320001851 | 1.69 | 74.2 | Palliative (P) | 2017-09-26 | 2017-10-08 | Cisplatin + Docetaxel +Fluorouracil | Y | null | 320018244 | CISPLATIN + GEMCITABINE |
| 320003095 | 320001852 | null | null | Palliative (P) | 2016-11-01 | 2016-11-02 | Carboplatin+Fluorouracil 4 or 5 day | 2 | null | 320018247 | ETOPOSIDE + IFOSFAMIDE |
| 320003096 | 320004944 | 1.51 | 55.2 | Palliative (P) | 2014-03-03 | 2014-03-29 | CETUXIMAB + RT | null | N | 320018252 | CETUXIMAB + CISPLATIN + FU |
| 320003097 | 320004944 | 1.59 | 59 | Palliative (P) | 2017-06-23 | 2017-06-29 | FEC 60 or 75 | Y | N | 320018252 | CARBOPLATIN + ETOPOSIDE |
| 320003098 | 320001853 | 1.58 | 70.5 | Curative (C) | 2016-03-11 | 2016-04-21 | PEMBROLIZUMAB | N | Y | 320018264 | CETUXIMAB + RT |